Targeting the PI3K/Akt/mTOR or MAPK pathway, especially with PI3K/mTOR dual inhibition, offered antitumor potentials in PTX-resistant GC, so this may represent a novel treatment strategy for PTX-resistant GC. Here, MTOR is linked to gastric cancer.